Showing 9861-9870 of 20874 results for "".
Reimagining GI Care: Digital Therapeutics for Managing IBS and IBD Symptoms
https://reachmd.com/programs/gi-insights/reimagining-gi-care-digital-therapeutics-for-managing-ibs-and-ibd-symptoms/36499/From symptom trackers to multidisciplinary app-based platforms, evidence-based digital therapeutics are expanding access to brain-gut behavioral care for patients with irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD). Dr. Peter Buch sits down with Dr. Iris Wang to discuss the specNavigating Iron Deficiency Anemia: A Practical Guide for Gastroenterologists
https://reachmd.com/programs/gi-insights/program-name/36501/Iron deficiency anemia is common in gastroenterology patients and is often underrecognized or suboptimally managed. That's why targeted treatment is essential to improve patient outcomes. In this expert-led discussion, Dr. Peter Buch and Dr. Thomas DeLoughery outline what gastroenterologists need tTreating Psoriasis Patients Who Vape: Barriers and Interventions
https://reachmd.com/programs/clinicians-roundtable/treating-psoriasis-patients-who-vape-barriers-and-interventions/36368/For dermatologists, treating psoriasis patients who use e-cigarettes can be challenging, particularly because of a lack of education about its risks, mental health concerns, and impacts on treatment efficacy. That being said, there are ways to address these challenges to support patients and improvePatient Perspectives on Subcutaneous vs IV Immunotherapies in Oncology Care
https://reachmd.com/programs/project-oncology/patient-perspectives-on-subcutaneous-vs-iv-immunotherapies-in-oncology-care/36402/How do real-world patients experience subcutaneous versus IV immunotherapies? That’s exactly what a first-of-its-kind U.S. study set out to uncover. Tune in to this Audio Abstract to hear the key findings published in Oncology and Therapy and how they could reshape patient-centered cancer care. RefeOptimizing Nivolumab in NSCLC: Implications for Cost, Access, and Outcomes
https://reachmd.com/programs/project-oncology/optimizing-nivolumab-in-nsclc-implications-for-cost-access-and-outcomes/32997/Emerging evidence suggests that combining low-dose nivolumab and chemotherapy in the neoadjuvant setting may retain immunologic efficacy while drastically lowering cost and toxicity for non-small cell lung cancer (NSCLC) patients. Additionally, this approach could help optimize trial design with dosCOVID-19 Recovery: Investigating the Link Between Inflammation and Cognitive Symptoms
https://reachmd.com/programs/clinicians-roundtable/covid-19-recovery-investigating-the-link-between-inflammation-and-cognitive-symptoms/35465/A post hoc analysis of the CONTAIN randomized clinical trial tracked inflammatory markers and health outcomes up to 18 months post-hospitalization. Based on the results, markers like cytokines, D-dimer, and fibrinogen declined over time, and no clear link was found between persistent inflammation anThe Complexities Behind Lupus: Understanding its Multifactorial Mechanisms
https://reachmd.com/programs/living-rheum/the-complexities-behind-lupus-understanding-its-multifactorial-mechanisms/32787/Lupus arises from a complex interaction of genetics, environmental stimuli, and immune system errors. Dive into the pathophysiology behind the disease with Dr. Michelle Kahlenberg, the Giles Boles and Dorothy Mulkey Research Professor of Rheumatology and Professor of Internal Medicine and DermatologEvaluating the Safety of Ixekizumab in Psoriasis and Arthritis Patients
https://reachmd.com/programs/clinicians-roundtable/evaluating-the-safety-of-ixekizumab-in-psoriasis-and-arthritis-patients/32447/Learn about the risk of adverse events associated with ixekizumab in patients with psoriasis, psoriatic arthritis, and axial spondyloarthritis.Nemluvio Gains Two Major Indications in Europe
https://reachmd.com/videos/dermwire-tv/nemluvio-gains-two-major-indications-in-europe/32982/In this week's DermwireTV, Nemluvio is approved for two new indications in Europe; new patient-centric guidelines for generalized pustular psoriasis (GPP) management are unveiled; and in our C-Suite Chats feature, we are joined by the Co-Founder and CEO of Veradermics.Dupilumab's Impact on Height, 40-GEP for HNcSCC Lead Posters at Maui Derm
https://reachmd.com/programs/practical-dermatology/dupilumabs-impact-on-height-40-gep-for-hncscc-lead-posters-at-maui-derm/32916/The impact of dupilumab on children’s height and the 40-gene expression profile (40-GEP) test for patients with cutaneous squamous cell carcinoma of the head and neck (HNcSCC) were the topics of the top two posters in the “Late Breakers 2025” session at Maui Derm 2025 in Maui, Hawaii.